Filtered By:
Specialty: Allergy & Immunology
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 1296 results found since Jan 2013.
Improvement of Lipoplexes With a Sialic Acid Mimetic to Target the C1858T PTPN22 Variant for Immunotherapy in Endocrine Autoimmunity
The C1858T variant of the protein tyrosine phosphatase N22 (PTPN22) gene is associated with pathophysiological phenotypes in several autoimmune conditions, namely, Type 1 diabetes and autoimmune thyroiditis. The R620W variant protein, encoded by C1858T, leads to a gain of function mutation with paradoxical reduced T cell activation. We previously exploited a novel personalized immunotherapeutic approach based on siRNA delivered by liposomes (lipoplexes, LiposiRNA) that selectively inhibit variant allele expression. In this manuscript, we functionalize lipoplexes carrying siRNA for variant C1858T with a high affinity ligand...
Source: Frontiers in Immunology - March 9, 2022 Category: Allergy & Immunology Source Type: research
The TL1A-DR3 Axis in Asthma: Membrane-Bound and Secreted TL1A Co-Determined the Development of Airway Remodeling
CONCLUSIONS: Our results confirm differential TL1A expression (including its secreted and non-secreted form) in asthma, which modulates remodeling. The shared mechanism of action by which nsTL1A and secreted TL1A exert their effects on asthma development might be mediated via the nuclear factor-κB pathway. The TL1A-DR3 axis presents a promising therapeutic target in asthma.PMID:35255540 | DOI:10.4168/aair.2022.14.2.233
Source: Allergy, Asthma and Immunology Research - March 7, 2022 Category: Allergy & Immunology Authors: Jintao Zhang Dong Zhang Yun Pan Xiaofei Liu Jiawei Xu Xinrui Qiao Wenjing Cui Liang Dong Source Type: research
Identification and validation of Osteopontin and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) for potential immunotherapeutic significance of in lung squamous cell carcinoma
CONCLUSIONS: By using integrated bioinformatics, we have identified CD168 and OPN as DEGs with poor prognosis in LUSC and have validated their interaction in the ECM receptor pathway. These genes could be potential diagnostic and therapeutic targets for LUSC patients undergoing immunotherapy.PMID:35334357 | DOI:10.1016/j.intimp.2022.108715
Source: International Immunopharmacology - March 25, 2022 Category: Allergy & Immunology Authors: Gao Shan Li Meihe Kang Minchao Zhao Rui Wen Xiaopeng Zhang Guangjian Zheng Jin Source Type: research
